WST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

New York, New York--(Newsfile Corp. - June 18, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired West securities between February 16, 2023 and February 12, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/WST.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/WST, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in West you have until July 7, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251009

The West Pharmaceutical Services Stock at the time of publication of the news with a raise of +0,05 % to 190,1EUR on Lang & Schwarz stock exchange (18. Juni 2025, 22:00 Uhr).